Related Experiment Video

Updated: Aug 10, 2026

An In vitro Model to Study Immune Responses of Human Peripheral Blood Mononuclear Cells to Human Respiratory Syncytial Virus Infection
09:01

An In vitro Model to Study Immune Responses of Human Peripheral Blood Mononuclear Cells to Human Respiratory Syncytial Virus Infection

Published on: December 10, 2013

Passive immunisation of preterm infants with palivizumab against RSV infection

Christian Harkensee1, Malcolm Brodlie, Nicholas D Embleton

  • 1Newcastle Neonatal Service, Department of Child Health, University of Newcastle upon Tyne, Royal Victoria Infirmary, Newcastle upon Tyne NE1 4LP, UK.

The Journal of Infection
|October 21, 2005
PubMed

Insights

Palivizumab shows clinical benefit for preventing respiratory syncytial virus (RSV) in preterm infants. However, current cost-effectiveness analyses do not support widespread use, recommending it only for high-risk infants.

Area of Science:

  • Pediatrics
  • Immunology
  • Health Economics

Background:

  • Respiratory syncytial virus (RSV) is a significant cause of infant hospitalization.
  • Palivizumab is a monoclonal antibody developed for RSV prevention.
  • Evidence on its efficacy, safety, and cost-effectiveness requires comprehensive review.

Purpose of the Study:

  • To review the existing literature on the efficacy, safety, and cost-effectiveness of palivizumab for RSV prevention.
  • To evaluate the clinical benefit and safety profile of palivizumab.
  • To assess the economic viability of palivizumab immunization programs.

Main Methods:

  • Literature review of randomized controlled trials and cost-effectiveness studies.
  • Analysis of clinical trial data regarding palivizumab efficacy and safety.
  • Examination of economic analyses comparing immunization costs with hospitalization savings.

Main Results:

  • A randomized controlled trial demonstrated clinical benefit and a favorable safety profile for palivizumab in preterm infants.
  • Further studies indicate that cost savings from reduced hospitalizations may not outweigh immunization costs.
  • Cost-effectiveness analyses are complicated by variable healthcare costs and RSV incidence.

Conclusions:

  • Palivizumab demonstrates efficacy and safety in specific high-risk infant populations.
  • Current cost-effectiveness data do not support broad implementation of palivizumab.
  • Recommendation is limited to infants at high risk for severe RSV bronchiolitis, such as those with chronic lung disease of prematurity.

More Related Videos

An Improved and High Throughput Respiratory Syncytial Virus (RSV) Micro-neutralization Assay09:14

An Improved and High Throughput Respiratory Syncytial Virus (RSV) Micro-neutralization Assay

Published on: January 26, 2019

Generation, Amplification, and Titration of Recombinant Respiratory Syncytial Viruses11:48

Generation, Amplification, and Titration of Recombinant Respiratory Syncytial Viruses

Published on: April 4, 2019

Related Concept Videos

Vaccinations01:51

Vaccinations

Overview
Active versus Passive Immunity01:31

Active versus Passive Immunity

Immunity, along with the ability to limit pathogen growth to prevent significant body tissue damage, can be gained either by (1) actively developing an immune response within the individual after exposure to a pathogen or after getting vaccinated or (2) passively transferring immune components from an immune individual to one who is nonimmune. Both these forms of immunity can be found naturally and in medical practices.
Active Immunity
Active immunity refers to the resistance one develops...
Development of Immunocompetence01:22

Development of Immunocompetence

The initiation of cell-mediated immunity can be observed as early as the third month of fetal growth, with active antibody-mediated immunity following approximately one month later.
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...
Poliomyelitis01:17

Poliomyelitis

Poliomyelitis is caused by poliovirus, a small, non-enveloped, positive-sense RNA virus of the Picornaviridae family and Enterovirus genus. Transmission occurs primarily via the fecal-oral route, often through ingestion of contaminated water or food. The virus initially replicates in the oropharynx and intestinal mucosa, particularly in lymphoid tissues such as the tonsils, Peyer’s patches, and regional lymph nodes. Primary viremia follows, allowing dissemination throughout the body.In most...
Rabies01:28

Rabies

Rabies is a lethal zoonotic disease caused by a single-stranded, negative-sense RNA virus of the Lyssavirus genus, within the family Rhabdoviridae. Its primary mode of transmission to humans is through bites or saliva-contaminated scratches from infected mammals such as dogs, bats, raccoons, or foxes. Transmission can also occur if infectious saliva contacts abraded skin or intact mucous membranes, including the conjunctiva.Viral Entry and Early ReplicationOnce introduced at the bite or scratch...
Respiratory Syncytial Virus Disease01:29

Respiratory Syncytial Virus Disease

Human respiratory syncytial virus (RSV) is a widespread pathogen that primarily targets infants and young children but also poses a serious health risk to elderly and immunocompromised individuals. Belonging to the Pneumoviridae family, RSV is a negative-sense, single-stranded RNA virus within the Pneumovirus genus. Its global health burden is significant, with millions of cases annually resulting in hospitalizations and mortality, particularly in resource-limited settings. Although most...